PlaqueTec appoints Dr Tim Brears as CEO

Cambridge firm is pioneering a biomarker-based approach to understanding coronary artery disease

PlaqueTec, a Cambridge, UK-based company pioneering the development of a biomarker-based approach to transform the understanding of coronary artery disease (CAD), has appointed Dr Tim Brears as Chief Executive.

Dr Brears until recently was Chief Executive of Xention, a developer of drugs for the control of atrial fibrillation, which he founded in 2002. Prior to this, he was Chief Executive of Gendaq, a gene-regulation company, which was acquired by Sangamo Biosciences in 2001.

From 1993 to 1999 he was Director of Licensing at Ciba-Geigy (later Novartis) Agribusiness in Research Triangle Park, North Carolina, US.

You may also like

Research & Development

PlaqueTec and the Babraham Institute collaborate on early phase target discovery and development

Campus Innovation Award (CIA)-funded project evaluated lead compounds predicted to bind a pro-inflammatory protein discovered by PlaqueTec
Research & Development

PlaqueTec and the Babraham Institute collaborate on the development of a phenotypic screen for coronary artery blood

PlaqueTec and the Abraham Institute have begun collaborations to develop a bespoke phenotypic assay for use in patients with coronary artery disease (CAD), allowing the identification of cell types commonly present in patient samples.
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Hybrid interferons: developing a novel drug class

With many hurdles to overcome, establishing a new drug candidate is a long process — particularly if you are a smaller biotech company with limited resources. These challenges can be further amplified if the candidate being developed is of an entirely novel drug class
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Manufacturing

Anton Paar expands Litesizer DIA Series with new models

Introducing affordable and advanced solutions for particle analysis
Manufacturing

Triple your efficiency with the new DrySyn Vortex

Boost productivity with temperature-controlled parallel reactions
Subscribe now